Anteris Secures Medtronic Backing in $320M Capital Raise to Push TAVR Program Forward

Minneapolis & Brisbane, January 22, 2026 (Globe Newswire) -- Anteris Technologies Global Corp. announced a $90 million strategic investment from Medtronic, bringing total gross proceeds to $320 million when combined with a concurrent underwritten equity offering. The funding will support execution of Anteris’ global pivotal PARADIGM trial and accelerate progress toward worldwide commercialization of its DurAVR® transcatheter heart valve for aortic stenosis. Company leaders said the investment validates Anteris’ valve technology and could broaden into deeper strategic collaboration as both firms aim to advance durability, hemodynamics, and long-term outcomes in the TAVR market.

Read full article here.